International Day Of Women in Statistics and Data Science

Lu (Maggie) Qian is an independent biostatistician and founder of Evidence in the Wild and Zetyra. Her work focuses on Bayesian and adaptive clinical trial design, regulatory alignment, prior specification, prior-data conflict, and operating characteristics of composed adaptive pipelines. She has submitted FDA comment letters on the 2026 draft Bayesian guidance and publishes the Evidence in the Wild essay series on Bayesian methods in clinical research; her writing has appeared in Significance. Her current collaboration with Robert A. J. Matthews develops fair-minded skeptical priors and reverse-Bayes regulatory diagnostics for Bayesian assessment of novel therapies. She will present an accepted contributed paper at JSM 2026 on validated, regulatory-aligned calculator design. She has more than 10 years of experience in oncology therapeutics and early detection clinical trials.